MapLight Therapeutics, Inc. Common Stock (MPLT) Stock Price
MPLTStock
$7.70
Market Cap$427.93M
P/E—
PEG Ratio—
Div yield—
Beta0.80
MPLT Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-81.41%
Price vs S&P 500 (4W)-28.03%
VGM Score13.12
MPLT Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$1.31 | -$1.32 | -0.96%(-$0.01) | |
| Q1 2026 | -$1.09 | -$1.34 | -22.94%(-$0.25) | |
| Q4 2025 | -$0.83 | -$2.47 | -197.59%(-$1.64) | |
| Q3 2025 | -$1.73 | -$37.18 | -2055.36%(-$35.46) |
MPLT Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.25
4.28
4.25
4.20
Industry Peers — Pharmaceuticals(574)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|---|---|---|
MPLTMapLight Therapeutics, Inc. Common Stock | — | — | F | — | — | — | — | $7.70 |
| LLYEli Lilly & Co. | D | B | A | 14.9x | 49.6% | 83.4% | 27.6% | $1257.03 |
| JNJJohnson & Johnson | D | C | B | 6.2x | 7.8% | 67.7% | 14.9% | $255.56 |
| ABBVABBVIE INC. | D | C | A | 7.8x | 10.4% | 72.8% | -2.9% | $285.42 |
| MRKMerck & Co., Inc. | D | C | A | 5.4x | 4.6% | 77.3% | 21.2% | $145.95 |
| NVSNovartis AG | C | C | B | 4.9x | 3.3% | 75.0% | 15.3% | $150.62 |
| AZNAstraZeneca PLC | C | B | B | 4.3x | 8.6% | 81.3% | 21.9% | $165.41 |
| ABTAbbott Laboratories | C | C | B | 3.9x | 8.1% | 56.8% | 8.2% | $104.89 |
| NVONovo-Nordisk A/S | B | C | C | 3.5x | 5.6% | 80.7% | 20.7% | $38.83 |
| PFEPfizer Inc. | C | D | A | 2.6x | -0.2% | 74.7% | -3.5% | $29.58 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | 10.1x | 10.2% | 86.0% | 8.3% | $499.74 |
About MapLight Therapeutics, Inc. Common Stock
MapLight Therapeutics is a biopharmaceutical company developing circuit-specific treatments for central nervous system disorders, targeting unmet needs in psychiatry and neuroscience. The company's differentiated approach focuses on targeting specific neural circuits rather than broad CNS pathways. Its pipeline includes multiple clinical-stage candidates, including ML-007C-MA, ML-004, ML-021, and ML-009.